Neurocrine Biosciences | NBIX - Trade Debtors


Neurocrine Biosciences reported $686.8M in Trade Debtors for its fiscal quarter ending in December of 2025.





Trade Debtors Change Date
AbbVie USD 12.77B 132M Sep/2025
Acadia Pharmaceuticals USD 148.23M 8.79M Dec/2025
Agios Pharmaceuticals USD 10.58M 5.55M Dec/2025
ALKERMES USD 334.02M 21.08M Dec/2025
Alnylam Pharmaceuticals USD 777.57M 187.2M Dec/2025
Amgen USD 9.57B 1.08B Dec/2025
Biogen USD 1.85B 234M Sep/2025
BioMarin Pharmaceutical USD 908.21M 117.95M Dec/2025
Cytokinetics USD 1.81M 6.6M Sep/2025
Enanta Pharmaceuticals USD 40.16M 1.52M Dec/2024
Exelixis USD 286.92M 24.38M Dec/2025
Gilead Sciences USD 4.91B 182M Dec/2025
Halozyme Therapeutics USD 441.27M 95.24M Dec/2025
Incyte USD 1.02B 128.52M Dec/2025
Ionis Pharmaceuticals USD 66M 41.39M Dec/2025
Nektar Therapeutics USD 0 2.9M Sep/2024
Neurocrine Biosciences USD 686.8M 41.2M Dec/2025
Pfizer USD 18.12B 2.02B Sep/2025
Prothena USD 5.16M 0 Dec/2023
Regeneron Pharmaceuticals USD 5.74B 54M Dec/2025
Repligen USD 158.59M 9.62M Dec/2025
Rigel Pharmaceuticals USD 28.9M 1.39M Jun/2024
Sarepta Therapeutics USD 398.23M 2.49M Dec/2025
Teva Pharmaceutical Industries USD 3.71B 101M Dec/2025
Ultragenyx Pharmaceutical USD 112.54M 11.92M Sep/2025
Vertex Pharmaceuticals USD 2.05B 106.4M Dec/2025
Xoma USD 14.78M 4.96M Jun/2024